ChinaDrugStatus
National Medical Products Administration (NMPA)

Verified China Drug Approvals

Launch release displays only manually verified NMPA approval records (7 records across 4 drugs) tied to our 2026 catalog sample. Approval dates and public announcement/delivery dates are stored separately.

Export CSV (7 rows)
Sample scope notice: Only records verified against official NMPA notices or MAH prescribing labels are listed here. Additional drugs in our 20-drug sample are checked weekly.NMPA Official Lookup Portal ↗
Approval DateDrug & Approval No.Event Type & Approved ScopeAuthority & MAHSource
Sep 16, 2025
2025-09-16
Mazdutide
玛仕度肽注射液
国药准字H20250036
0.5ml:2mg / 4mg / 6mg
Supplemental Indication

Glycemic control in adults with Type 2 Diabetes mellitus (monotherapy or in combination with oral antidiabetic agents); covers H20250036 / H20250037 / H20250038.

本品适用于成人2型糖尿病患者的血糖控制(单药治疗或联合二甲双胍等口服降糖药)。

NMPA (China)
Innovent Biologics (Suzhou) Co., Ltd.
信达生物制药(苏州)有限公司
Verified 2026-11-20
Jun 24, 2025
2025-06-24
Notice: 2025-06-30
Mazdutide
玛仕度肽注射液
国药准字H20250036
0.5ml:2mg
Initial Approval

Chronic weight management in adults as an adjunct to diet and physical activity (initial BMI ≥ 28 kg/m² obesity, or BMI ≥ 24 kg/m² overweight with at least one weight-related comorbidity).

本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

NMPA (China)
Innovent Biologics (Suzhou) Co., Ltd.
信达生物制药(苏州)有限公司
Verified 2026-11-20
Jun 24, 2025
2025-06-24
Notice: 2025-06-30
Mazdutide
玛仕度肽注射液
国药准字H20250037
0.5ml:4mg
Initial Approval

Chronic weight management in adults (4 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).

本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

NMPA (China)
Innovent Biologics (Suzhou) Co., Ltd.
信达生物制药(苏州)有限公司
Verified 2026-11-20
Jun 24, 2025
2025-06-24
Notice: 2025-06-30
Mazdutide
玛仕度肽注射液
国药准字H20250038
0.5ml:6mg
Initial Approval

Chronic weight management in adults (6 mg presentation); same initial NMPA approval date (2025-06-24) and delivery notice (2025-06-30).

本品适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制,初始体重指数(BMI)为:BMI ≥ 28 kg/m²(肥胖),或 BMI ≥ 24 kg/m²(超重)并伴有至少一种体重相关的合并症。

NMPA (China)
Innovent Biologics (Suzhou) Co., Ltd.
信达生物制药(苏州)有限公司
Verified 2026-11-20
Dec 25, 2024
2024-12-25
Notice: 2024-12-31
Zolbetuximab
注射用佐妥昔单抗
国药准字SJ20240050
100mg/瓶
Initial Approval

First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.

联合含氟尿嘧啶类和铂类药物化疗,用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。

NMPA (China)
Astellas Pharma
安斯泰来制药
Verified 2026-11-20
Nov 27, 2024
2024-11-27
Notice: 2024-11-27
Sacituzumab tirumotecan
注射用芦康沙妥珠单抗
国药准字S20240052
200mg/瓶
Initial Approval

Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting).

用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者。

NMPA (China)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科伦博泰生物医药股份有限公司
Verified 2026-11-20
Sep 1, 2021
2021-09-01
Notice: 2021-09-03
Relmacabtagene autoleucel
瑞基奥仑赛注射液
国药准字S20210035
Initial Approval

Adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy; subsequently expanded to r/r FL and r/r MCL.

经过二线或以上系统性治疗后成人患者的复发或难治性大B细胞淋巴瘤(r/r LBCL);后续获批滤泡性淋巴瘤(FL)及套细胞淋巴瘤(MCL)适应症。

NMPA (China)
JW Therapeutics (Shanghai) Co., Ltd.
上海药明巨诺生物科技有限公司
Verified 2026-11-20